Drug Trial News

RSS

Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

11 Feb 2024

Selective androgen receptor modulator has anti-tumor effects in ER-positive breast cancer patients

A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.

8 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

First gene therapy trial aims to restore hearing in children

The aim of this clinical trial, which has just received approval in France, is to assess the safety and efficacy of a new gene therapy drug in children aged between 6 and 31 months with profound hearing loss.

5 Feb 2024

Clinical trials becoming more inclusive across race and ethnicity, new data shows

Clinical trials and medical research have been historically lacking in diversity among all groups.

5 Feb 2024

Phase 3 trial of new malaria vaccine reveals promising results in protecting children

Today, peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M™ malaria vaccine were published in The Lancet. The study was conducted across multiple sites in four African countries with 4,800 children aged 5-36 months.

5 Feb 2024

Phase II clinical trial evaluates the safety and efficacy of a Muse cell-based product in patients with ALS

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its onset.

1 Feb 2024

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.

29 Jan 2024

Immunotherapy drug extends overall survival in kidney cancer patients after surgery

For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.

27 Jan 2024

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

27 Jan 2024

Clinical study supports the long-lasting impacts of typhoid conjugate vaccine

A single dose of the typhoid conjugate vaccine, Typbar TCV, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study conducted by researchers at University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health (CVD) and led by in-country partners at the Malawi-Liverpool Wellcome Trust (MLW) Clinical Research Programme.

25 Jan 2024

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds

The efficacy of the controlled release of low-dose morphine as treatment against that of a placebo in idiopathic pulmonary fibrosis.

18 Jan 2024

Phase 3 trial shows acoramidis safe and effective for transthyretin amyloid cardiomyopathy

Pumping over 100,000 times a day, the heart is a critical muscle needed to deliver oxygen and nutrients to our organs to sustain healthy bodily function.

16 Jan 2024

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome.

16 Jan 2024

Groundbreaking drug offers new hope for life-threatening heart condition

People diagnosed with a life-threatening cardiac condition have been given new hope, thanks to a ground-breaking new drug that protects the heart developed by researchers from UCL and the Royal Free Hospital.

11 Jan 2024

University of Oxford launches first-in-human trial of the ChAdOx1 NipahB vaccine

The University of Oxford has launched a new clinical trial to test a vaccine to protect people against deadly Nipah virus.

11 Jan 2024

Extended liver preservation technique shows promise for daytime transplants

Phase II clinical trial evaluates the safety and feasibility of prolonged DHOPE for extending human donor liver preservation to 20 hours, showing potential for facilitating daytime liver transplantation.

11 Jan 2024

Carvedilol improves heart health marker in childhood cancer survivors

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children's Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

9 Jan 2024

Previous
1
...
8
9
10
11
12
13
14
...
1143
Next

Drug Trial News

Drug repurposing study finds lonafarnib effective against RSV

Selective androgen receptor modulator has anti-tumor effects in ER-positive breast cancer patients

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

First gene therapy trial aims to restore hearing in children

Clinical trials becoming more inclusive across race and ethnicity, new data shows

Phase 3 trial of new malaria vaccine reveals promising results in protecting children

Phase II clinical trial evaluates the safety and efficacy of a Muse cell-based product in patients with ALS

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Immunotherapy drug extends overall survival in kidney cancer patients after surgery

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Clinical study supports the long-lasting impacts of typhoid conjugate vaccine

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Morphine shows potential as effective cough therapy for pulmonary fibrosis, study finds

Phase 3 trial shows acoramidis safe and effective for transthyretin amyloid cardiomyopathy

Vanderbilt launches $13 million trial to test repurposed drugs for Rett syndrome

Groundbreaking drug offers new hope for life-threatening heart condition

University of Oxford launches first-in-human trial of the ChAdOx1 NipahB vaccine

Extended liver preservation technique shows promise for daytime transplants

Carvedilol improves heart health marker in childhood cancer survivors

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News